{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:03:54Z","timestamp":1787501034858,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,8,26]],"date-time":"2015-08-26T00:00:00Z","timestamp":1440547200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s00774-015-0709-8","type":"journal-article","created":{"date-parts":[[2015,8,25]],"date-time":"2015-08-25T03:22:40Z","timestamp":1440472960000},"page":"646-654","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early DIagnosis and Treatment of OsteopoRosis in Japan (EDITOR-J) study"],"prefix":"10.1007","volume":"34","author":[{"given":"Yoshiya","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatoshi","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kawahito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisanori","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Tohma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Yamanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhide","family":"Tanimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Negoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukitaka","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,26]]},"reference":[{"key":"709_CR1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMcp1012926","volume":"365","author":"RS Weinstein","year":"2011","unstructured":"Weinstein RS (2011) Glucocorticoid-induced bone disease. N Engl J Med 365:62\u201370","journal-title":"N Engl J Med"},{"key":"709_CR2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200084","volume":"13","author":"TP Staa van","year":"2002","unstructured":"van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporosis Int 13:777\u2013787","journal-title":"Osteoporosis Int"},{"key":"709_CR3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0169-6009(91)90139-Q","volume":"8","author":"V LoCascio","year":"1990","unstructured":"LoCascio V, Bonucci E, Imbimbo B, Ballanti P, Adami S, Milani S, Tartarotti D, DellaRocca C (1990) Bone loss in response to long-term glucocorticoid therapy. Bone Miner 8:39\u201351","journal-title":"Bone Miner"},{"key":"709_CR4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00774-004-0596-x","volume":"23","author":"H Nawata","year":"2005","unstructured":"Nawata H, Soen S, Takayanagi R, Tanaka I, Takaoka K, Fukunaga M, Matsumoto T, Suzuki Y, Tanaka H, Fujiwara S, Miki T, Sagawa A, Nishizawa Y, Seino Y; Subcommittee to Study Diagnostic for Glucocorticoid-Induced Osteoporosis (2005) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of The Japanese Society for Bone and Mineral Research (2004 edition). J Bone Miner Metab 23:105\u2013109","journal-title":"J Bone Miner Metab"},{"key":"709_CR5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/s10165-005-0391-0","volume":"15","author":"S Soen","year":"2005","unstructured":"Soen S, Tanaka Y (2005) Glucocorticoid-induced osteoporosis: skeletal manifestations of glucocorticoid use and 2004 Japanese Society for Bone and Mineral Research-proposed guidelines for its management. Mod Rheumatol 15:163\u2013168","journal-title":"Mod Rheumatol"},{"key":"709_CR6","first-page":"163","volume":"31","author":"S Nakayamada","year":"2004","unstructured":"Nakayamada S, Okada Y, Saito K, Tanaka Y (2004) Etidronate prevents high-dose glucocorticoid-induced bone loss in premenopausal individuals with systemic autoimmune diseases. J Rheumatol 31:163\u2013169","journal-title":"J Rheumatol"},{"key":"709_CR7","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3899\/jrheum.080168","volume":"35","author":"Y Okada","year":"2008","unstructured":"Okada Y, Nawata M, Nakayamada S, Saito K, Tanaka Y (2008) Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. J Rheumatol 35:2249\u20132254","journal-title":"J Rheumatol"},{"key":"709_CR8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/00002281-200107000-00015","volume":"13","author":"JA Clowers","year":"2001","unstructured":"Clowers JA, Peel N, Eastell R (2001) Glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 13:326\u2013332","journal-title":"Curr Opin Rheumatol"},{"key":"709_CR9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1210\/endo.131.1.1611989","volume":"131","author":"DJ Defranco","year":"1992","unstructured":"Defranco DJ, Lian JB, Glowacki J (1992) Differential effects of glucocorticoid on recruitment and activity of osteoclasts induced by normal and osteocalcin-deficient bone implanted in rats. Endocrinology 131:114\u2013121","journal-title":"Endocrinology"},{"key":"709_CR10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1297-319X(03)00016-2","volume":"70","author":"MH Lafage-Proust","year":"2003","unstructured":"Lafage-Proust MH, Boudignon B, Thomas T (2003) Glucocorticoid-induced osteoporosis: pathophysiological data and recent treatments. Joint Bone Spine 70:109\u2013118","journal-title":"Joint Bone Spine"},{"key":"709_CR11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0049-0172(00)80011-6","volume":"29","author":"JD Adachi","year":"2000","unstructured":"Adachi JD, Olszynski WP, Hanley DA, Hodsman AB, Kendler DL, Siminoski KG, Brown J, Cowden EA, Goltzman D, Ioannidis G, Josse RG, Ste-Marie LG, Tenenhouse AM, Davison KS, Blocka KL, Pollock AP, Sibley J (2000) Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum 29:228\u2013251","journal-title":"Semin Arthritis Rheum"},{"key":"709_CR12","unstructured":"Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. (2000) American College of Rheumatology Ad Hoc Committee on Glucocorticoid-induced Osteoporosis. Arthritis Rheum 44:1496\u20131503"},{"key":"709_CR13","unstructured":"Royal College of Physicians. (2002) Glucocorticoid-induced osteoporosis: guidelines on osteoporosis society and royal college of physicians, London"},{"key":"709_CR14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s001980050118","volume":"9","author":"JY Reginster","year":"1999","unstructured":"Reginster JY, Kuntz D, Verdickt W, Wouters M, Guillevin L, Mekes CJ, Nielsen K (1999) Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporosis Int 9:75\u201381","journal-title":"Osteoporosis Int"},{"key":"709_CR15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00774-014-0586-6","volume":"32","author":"Y Suzuki","year":"2015","unstructured":"Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H, Tanaka I, Ozono K, Sagawa A, Takayanagi R, Tanaka H, Miki T, Masunari N, Tanaka Y (2015) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab 32:337\u2013350","journal-title":"J Bone Miner Metab"},{"key":"709_CR16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s002239900708","volume":"65","author":"JD Ringe","year":"1999","unstructured":"Ringe JD, C\u00f6ster A, Meng T, Schacht E, Umback R (1999) Treatment of glucocorticoid-induced osteoporosis with alfacalcidol\/calcium versus vitamin D\/calcium. Calcif Tissue Int 65:337\u2013340","journal-title":"Calcif Tissue Int"},{"key":"709_CR17","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1359\/jbmr.2003.18.5.919","volume":"18","author":"PN Sambrook","year":"2003","unstructured":"Sambrook PN, Kotowicz M, Nash P, Styles CB, Naganathan V, Henderson-Briffa KN, Eisman JA, Nicholson GC (2003) Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 18:919\u2013924","journal-title":"J Bone Miner Res"},{"key":"709_CR18","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1359\/jbmr.2002.17.8.1512","volume":"17","author":"S Amin","year":"2002","unstructured":"Amin S, Lavalley MP, Simms RW, Felson DT (2002) The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 17:1512\u20131526","journal-title":"J Bone Miner Res"},{"key":"709_CR19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00198-004-1614-5","volume":"15","author":"RN Nijs de","year":"2004","unstructured":"de Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW (2004) Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporosis Int 15:589\u2013602","journal-title":"Osteoporosis Int"},{"key":"709_CR20","first-page":"34","volume":"11","author":"D Felsenberg","year":"2011","unstructured":"Felsenberg D, Bock O, B\u00f6rst H, Armbrecht G, Beller G, Degner C, Stephan-Oelkers M, Schacht E, Mazor Z, Hashimoto J, Roth HJ, Martus P, Runge M (2011) Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass. J Musculoskelet Neuronal Interact 11:34\u201345","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"709_CR21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00296-006-0288-z","volume":"27","author":"JD Ringe","year":"2007","unstructured":"Ringe JD, Farahmand P, Schacht E, Rozehnal A (2007) Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol Int 27:425\u2013434","journal-title":"Rheumatol Int"},{"key":"709_CR22","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1185\/03007995.2011.580341","volume":"27","author":"H Orimo","year":"2011","unstructured":"Orimo H, Nakamura T, Fukunaga M, Ohata H, Hosoi T, Uemura Y, Kuroda T, Miyakawa N, Ohashi Y, Shiraki M; A-TOP (Adequate Treatment of Osteoporosis) research group (2011) Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT)\u201402. Curr Med Res Opin 27:1273\u20131284","journal-title":"Curr Med Res Opin"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-015-0709-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-015-0709-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-015-0709-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-015-0709-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T02:16:57Z","timestamp":1559096217000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-015-0709-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,26]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["709"],"URL":"https:\/\/doi.org\/10.1007\/s00774-015-0709-8","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,26]]}}}